Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

Item

http://www.wikidata.org/entity/Q42209182

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

@en

Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

@nl

type

Item

label

Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

@en

Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

@nl

prefLabel

Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

@en

Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

@nl

P1476

Advances in Overcoming Immune Responses following Hemophilia Gene Therapy

@en

P2093

Carol H Miao

http://www.w3.org/2001/XMLSchema#string

P2860

A robust system for production of minicircle DNA vectors

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.

Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.

Adeno-associated virus serotypes: vector toolkit for human gene therapy.

In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses.

Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.

Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.

A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.

Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.

P31

scholarly article

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22737594

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

gene therapy

P932

3379895

http://www.w3.org/2001/XMLSchema#string